GeoVax Labs, Inc., a clinical-stage biotechnology company, announced that its Chief Medical Officer and clinical collaborators will present data on the company's next-generation COVID-19 vaccine, GEO-CM04S1, at two international scientific meetings in September 2025. The presentations will focus on the vaccine's performance in immunocompromised patients with hematologic malignancies, demonstrating cross-variant antibody and robust cellular immune responses.
At the 6th ESCMID Conference on Vaccines in Lisbon, Portugal from September 10-13, 2025, Chief Medical Officer Kelly T. McKee, Jr., MD, MPH will present a poster titled "GEO-CM04S1, a multi-antigen COVID-19 vaccine for immunocompromised individuals: clinical evaluation to date." For more information on this conference, visit https://www.escmid.org/congress-events/6th-escmid-conference-on-vaccines.
At the International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2025) in Krakow, Poland from September 12-15, 2025, Professor Alexey V. Danilov, MD, PhD from City of Hope National Medical Center will present findings from a Phase II randomized study. His poster, titled "MVA-based GEO-CM04S1 vaccine results in improved cellular immune response in patients with chronic lymphocytic leukemia (CLL) compared with mRNA-based vaccine: initial results," will be presented on September 15, 2025. Conference details are available at https://www.iwcll.org/events/xxi-iwcll-12-15-september-2025-krakow-poland/.
The GEO-CM04S1 vaccine is currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients, including those with hematologic cancers, for whom current authorized COVID-19 vaccines have shown insufficient protection. It is also being studied as a booster vaccine in patients with chronic lymphocytic leukemia and as a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines.
This development is significant because immunocompromised patients, particularly those with hematologic malignancies, represent a vulnerable population that has experienced suboptimal protection from existing COVID-19 vaccines. The demonstration of improved cellular immune responses in these patients could lead to better protection against severe COVID-19 outcomes and reduce mortality in this high-risk group. The multi-antigen approach may also provide broader protection against emerging variants, addressing a critical limitation of current vaccines.
The presentation of these clinical data at major international scientific conferences indicates the scientific community's interest in addressing vaccine limitations for immunocompromised populations and could influence future vaccine development strategies for vulnerable patient groups worldwide.
